Chronic kidney disease and diabetes: New renal and cardiovascular outcomes - Industry Symposium Supported by Sciarc GmbH

Session description - People with chronic kidney disease and type 2 diabetes are three times more likely to die from a cardiovascular-related cause than those with type 2 diabetes alone. The symposium will address unmet needs in the treatment of diabetic kidney disease and presents strategies to reduce the burden. New data on kidney failure and disease progression of chronic kidney disease will be presented. Outcomes of the FIDELIO-DKD Phase III study among patients with chronic kidney disease and type 2 diabetes will be highlighted. In the study, finerenone significantly lowered the combined risk of cardiovascular events, with comparable treatment efficacy for patients with or without history of cardiovascular disease. Finerenone is a first-in-class investigational non-steroidal, selective mineralocorticoid receptor (MR) antagonist that specifically addresses MR overactivation, a key driver of disease progression. The symposium will also focus on the clinical and practical aspects of mineralocorticoid antagonists in chronic kidney disease and type 2 diabetes.